Vindesine
- Atc Codes:L01CA03
- CAS Codes:53643-48-4
- PHARMGKB ID:53643-48-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Eldisin; Belgium: Eldisine; Finland: Eldisine; France: Eldisine; Germany: Eldisine, Gesidine; Greece: Eldesine, Gesidine; Italy: Eldisine; Luxembourg: Eldisine; Portugal: Gesidine; Spain: Enisón; Sweden: Eldisine.
Asia
Japan: Fildesin.
Drug combinations
Chemistry
Vindesine: C~43~H~55~N~5~O~7~. Mw: 753.93. (1) Vincaleukoblastine, 23-amino-O^4^-deacetyl-23-demethoxy-; (2) 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine. CAS-53643-48-4 (1976).
Pharmacologic Category
Antineoplastic Agents, Vinca Alkaloid. Natural Source (Plant) Derivative. (ATC-Code: L01CA03).
Mechanism of action
Vindesine arrests cell division in metaphase through inhibition of microtubular formation of mitotic spindle.
Therapeutic use
Investigational: Management of acute lymphocytic leukemia, chronic myelogenous leukemia. Breast, head, neck, and lung cancers. Lymphomas (Hodgkin’s and non-Hodgkin).
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to vindesine, vinca alkaloids, or any component of the formulation.
Warnings and precautions
Hazardous agent. Use with caution (if at all) in hepatic impairment, or in neurologic problems. Vindesine reported to display cross-resistance with vincristine. Not for intrathecal administration (may be fatal).